Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Metformin may ameliorate inflammatory events of il-18 in some inflammatory conditions

Ajil A. Alzamily, Karrar M. Obaid, Buthainah Al-Azzawi

. 2022 ; 91 (3) : 170-181. [pub] 20220902

Jazyk angličtina Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc22021738

Background: Interleukin-18 (IL-18) belongs to the cytokine family IL-1. IL-18 is synthesized as inactive precursors which need to be processed into an active interleukin by the Caspase-1 enzyme. The role of IL-18 is implicated in several auto-immune disorders, myocardial function, emphysema, metabolic syndromes, psoriasis, bowel inflammation, sepsis, and acute kidney injury. IL-18 exhibits pro-inflammatory properties, such as increased cell adhesion molecules, nitric oxide production, enhancement of T-cell and natural killer cell maturation, and increasing the production of chemokines. This study was designed from November 2020 to February 2021 at Al-Shomali hospital, Babylon governorate, Iraq. This study aimed to assess the levels of IL-18 in patients with PCOS, T2DM and CAD before treatment with metformin and after metformin medication, and to evaluate the roles of IL-18 in the development of this disease. Materials and methods: The study design is a case-control study and patients are selected by simple randomization after diagnosis by a specialist based on clinical diagnosis and laboratory findings. An enzyme-linked immunosorbent test (ELISA) was used to estimate the level of serum IL-18 before and after metformin administration. A total of 300 patients were involved in this study, divided according to their chronic illness as 60 women with PCOS, 60 patients Type 2 diabetes mellitus (T2DM), 60 patients with myocardial infarction (MI), and 60 patients with T2DM and MI. In addition, 30 healthy people as a control group. Results: Before treatment with metformin, the results were exhibited a significant difference (P≤0.0001) in the concentrations of IL-18 in PCOS, T2DM, and patients with CAD as compared with control. While, after metformin treatment, a significant decrease (P≤0. 01, P≤0.0001 and P≤0.001) in IL-18 level in patients with PCOS and T2DM and CAD respectively as compared to before metformin treatment. Conclusion: Metformin administration reduces the inflammatory events of IL-18 in patients with T2DM and CAD and PCOS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22021738
003      
CZ-PrNML
005      
20221111092850.0
007      
ta
008      
220920s2022 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.31482/mmsl.2021.039 $2 doi
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Alzamily, Ajil A. $u University of AL-Qadisiyah; College of Medicine, Iraq
245    10
$a Metformin may ameliorate inflammatory events of il-18 in some inflammatory conditions / $c Ajil A. Alzamily, Karrar M. Obaid, Buthainah Al-Azzawi
520    9_
$a Background: Interleukin-18 (IL-18) belongs to the cytokine family IL-1. IL-18 is synthesized as inactive precursors which need to be processed into an active interleukin by the Caspase-1 enzyme. The role of IL-18 is implicated in several auto-immune disorders, myocardial function, emphysema, metabolic syndromes, psoriasis, bowel inflammation, sepsis, and acute kidney injury. IL-18 exhibits pro-inflammatory properties, such as increased cell adhesion molecules, nitric oxide production, enhancement of T-cell and natural killer cell maturation, and increasing the production of chemokines. This study was designed from November 2020 to February 2021 at Al-Shomali hospital, Babylon governorate, Iraq. This study aimed to assess the levels of IL-18 in patients with PCOS, T2DM and CAD before treatment with metformin and after metformin medication, and to evaluate the roles of IL-18 in the development of this disease. Materials and methods: The study design is a case-control study and patients are selected by simple randomization after diagnosis by a specialist based on clinical diagnosis and laboratory findings. An enzyme-linked immunosorbent test (ELISA) was used to estimate the level of serum IL-18 before and after metformin administration. A total of 300 patients were involved in this study, divided according to their chronic illness as 60 women with PCOS, 60 patients Type 2 diabetes mellitus (T2DM), 60 patients with myocardial infarction (MI), and 60 patients with T2DM and MI. In addition, 30 healthy people as a control group. Results: Before treatment with metformin, the results were exhibited a significant difference (P≤0.0001) in the concentrations of IL-18 in PCOS, T2DM, and patients with CAD as compared with control. While, after metformin treatment, a significant decrease (P≤0. 01, P≤0.0001 and P≤0.001) in IL-18 level in patients with PCOS and T2DM and CAD respectively as compared to before metformin treatment. Conclusion: Metformin administration reduces the inflammatory events of IL-18 in patients with T2DM and CAD and PCOS.
650    _7
$a lidé $7 D006801 $2 czmesh
650    17
$a metformin $x farmakologie $x terapeutické užití $7 D008687 $2 czmesh
650    _7
$a interleukin-8 $x účinky léků $7 D016209 $2 czmesh
650    _7
$a diabetes mellitus $x farmakoterapie $7 D003920 $2 czmesh
650    _7
$a zánět $x farmakoterapie $7 D007249 $2 czmesh
650    _7
$a cytokiny $x účinky léků $7 D016207 $2 czmesh
650    _7
$a klinická studie jako téma $7 D000068456 $2 czmesh
700    1_
$a Obaid, Karrar M. $u Medical Laboratory Department, Al-Shomaliʼs hospital, Babylon, Iraq
700    1_
$a Al-Azzawi, Buthainah $u University of AL-Qadisiyah; College of Medicine, Iraq
773    0_
$t Vojenské zdravotnické listy $x 0372-7025 $g Roč. 91, č. 3 (2022), s. 170-181 $w MED00011116
856    41
$u https://mmsl.cz/artkey/mms-202203-0001_metformin-may-ameliorate-inflammatory-events-of-il-18-in-some-inflammatory-conditions.php $y plný text volně přístupný
910    __
$a ABA008 $b A 3 $c 1073 $y p $z 0
990    __
$a 20220909 $b ABA008
991    __
$a 20221111092842 $b ABA008
999    __
$a ok $b bmc $g 1840083 $s 1173006
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 91 $c 3 $d 170-181 $e 20220902 $i 0372-7025 $m Vojenské zdravotnické listy $x MED00011116
LZP    __
$c NLK109 $d 20221021 $b NLK111 $a Actavia-MED00011116-20220909

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...